Brief: Ipsen Shares First Aesthetic Data For IPN10200 In Phase II Trial

Ipsen SA

22/09/2025 06:10

Sept 22 (Reuters) - Ipsen SA IPN.PA:

IPSEN’S LANTIC PHASE II IN AESTHETICS DELIVERS A FIRST-IN-CLASS, DIFFERENTIATED LONG-ACTING CLINICAL PROFILE FOR IPN10200, ENABLING THE INITIATION OF PHASE III

IPN10200 SHOWS SIGNIFICANT IMPROVEMENT AT WEEK 4

DATA TO BE PRESENTED IN SCIENTIFIC CONFERENCE IN H1 2026

LONGER DURATION OF EFFECT OBSERVED AT WEEK 24

Source text: ID:nGNE9QG03L

Further company coverage: IPN.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))